Major international regulatory action including TGA and FDA was taken against a number of implants shown to carry a higher risk of Breast implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). This action was based on a greater understanding of risk and pathogenesis of BIA-ALCL and cited work published by our group at Macquarie University.